What is HC Wainwright's Forecast for PMVP FY2026 Earnings?

Key Points

• HC Wainwright has issued a FY2026 earnings estimate for PMV Pharmaceuticals, projecting a loss of ($1.63) per share, which is significantly lower than the consensus estimate of ($1.06) per share.
• PMV Pharmaceuticals reported a quarterly loss of ($0.41) EPS, missing analysts' expectations of ($0.39) by ($0.02) in its latest earnings release.
• Insider trading activity included CEO David Henry Mack selling 58,411 shares, resulting in a 9.82% decrease in ownership, while major shareholder Orbimed Advisors sold 500,000 shares for $900,000.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - HC Wainwright issued their FY2026 EPS estimates for PMV Pharmaceuticals in a research report issued on Friday, September 19th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($1.63) per share for the year. The consensus estimate for PMV Pharmaceuticals' current full-year earnings is ($1.06) per share.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02).

PMV Pharmaceuticals Stock Up 2.3%

Shares of PMVP stock traded up $0.03 during trading on Monday, reaching $1.34. The company's stock had a trading volume of 581,105 shares, compared to its average volume of 2,766,733. The company has a market cap of $71.01 million, a price-to-earnings ratio of -0.85 and a beta of 1.52. PMV Pharmaceuticals has a one year low of $0.81 and a one year high of $1.84. The business has a fifty day moving average price of $1.41 and a 200-day moving average price of $1.17.

Hedge Funds Weigh In On PMV Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Shay Capital LLC bought a new position in shares of PMV Pharmaceuticals during the second quarter worth approximately $26,000. Stonepine Capital Management LLC increased its stake in PMV Pharmaceuticals by 34.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 845,968 shares of the company's stock worth $897,000 after acquiring an additional 215,785 shares during the period. BML Capital Management LLC raised its holdings in PMV Pharmaceuticals by 33.4% in the 2nd quarter. BML Capital Management LLC now owns 5,000,000 shares of the company's stock valued at $5,300,000 after acquiring an additional 1,252,388 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of PMV Pharmaceuticals by 0.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,066,137 shares of the company's stock valued at $2,188,000 after acquiring an additional 18,960 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in shares of PMV Pharmaceuticals by 128.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 263,059 shares of the company's stock worth $279,000 after purchasing an additional 148,021 shares in the last quarter. 90.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at PMV Pharmaceuticals

In related news, insider Deepika Jalota sold 33,065 shares of PMV Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total transaction of $35,048.90. Following the completion of the sale, the insider directly owned 89,959 shares of the company's stock, valued at approximately $95,356.54. This trade represents a 26.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David Henry Mack sold 58,411 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $61,915.66. Following the completion of the transaction, the chief executive officer directly owned 536,133 shares in the company, valued at approximately $568,300.98. This represents a 9.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 614,627 shares of company stock worth $1,021,505 over the last 90 days. Company insiders own 7.60% of the company's stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.